Colorectal cancers with distinct metastatic potential trigger divergent early T cell responses
Colorectal cancer (CRC) remains a leading cause of mortality, with most cases refractory to immunotherapy. Distinguishing tumor-induced from steady-state mucosal T cell responses represents a critical barrier to understanding CRC immunity. Using orthotopic transplantation of CRC organoids with and without metastatic potential, combined with T cell fate-mapping, we show that nonmetastatic tumors elicit early recruitment of CD8αβ+ and CD4+ T cells with cytotoxic and Th1-like programs, whereas pro-metastatic (pro-Met) tumors induce a naïve-like, hypoactivated state. Tumor-infiltrating CD4+ T cells underwent clonal expansion, including clones recognizing microbial and dietary antigens. T cells physically interacting with tumors, identified by universal LIPSTIC, were enriched for expanded and cytotoxic clones. Fate-mapped T cells from nonmetastatic tumors suppressed tumor growth in an IFN-γ-dependent manner. Mechanistically, pro-Met tumors downregulated MHCII, and Ciita targeting in nonmetastatic organoids reduced CD4+ clonal expansion and led to tumor progression. Together, these findings define divergent early T cell trajectories associated with CRC metastasis, indicating that ineffective local immune engagement precedes metastatic dissemination.
Authors
- Sebastian E. Carrasco (ORCID: https://orcid.org/0000-0002-1926-7296)
- Norihiro Goto
- Sohail F. Tavazoie (ORCID: https://orcid.org/0000-0002-4966-9018)
- Izabela Mamede (ORCID: https://orcid.org/0000-0002-0707-5588)
- Marwa Saad (ORCID: https://orcid.org/0009-0009-4784-7747)
- Angelina Morand Bianchi Bilate (ORCID: https://orcid.org/0000-0003-4575-786X)
- Patrick W. Darcy (ORCID: https://orcid.org/0000-0002-7696-3212)
- Daniel Mucida (ORCID: https://orcid.org/0000-0002-0000-0452)
- Afsana Rahman (ORCID: https://orcid.org/0000-0002-2294-8690)
- Ruonan Chen (ORCID: https://orcid.org/0000-0003-1758-6151)
- Yue S. Yin
- Alexandra Thoms (ORCID: https://orcid.org/0009-0006-4169-061X)
Institutions
- Memorial Sloan Kettering Cancer Center (US)
- Howard Hughes Medical Institute (US)
- Cornell University (US)
- Weill Cornell Medicine (US)
- Rockefeller University (US)
Publication Details
- Journal
- The Journal of Experimental Medicine
- Published
- 2026-10-26
- DOI
- https://doi.org/10.1084/jem.20261199
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Howard Hughes Medical Institute
- Chan Zuckerberg Initiative
- National Institutes of Health
- National Cancer Institute
- National Institute of Diabetes and Digestive and Kidney Diseases